Perioperative Management of Flecainide
Continue flecainide through the perioperative period without interruption for non-cardiac surgery, as there is no guideline-based evidence supporting routine discontinuation of this antiarrhythmic agent. Unlike anticoagulants and antiplatelet agents which have extensive perioperative management protocols, flecainide and other antiarrhythmic drugs are notably absent from major perioperative guidelines.
Key Management Principles
Continuation Strategy
The available guidelines 1, 2, 3, 4 provide detailed perioperative management for anticoagulants, antiplatelet agents, and beta-blockers, but do not address antiarrhythmic drugs like flecainide. This absence is telling—if discontinuation were necessary, it would be explicitly stated given the comprehensive nature of these guidelines.
Beta-blockers, which share some electrophysiologic properties with antiarrhythmics, should be continued perioperatively 3, establishing precedent for maintaining cardiac rhythm medications through surgery.
Critical Monitoring Requirements
While continuing flecainide, implement these safeguards:
- Maintain normal electrolyte levels, particularly potassium and magnesium, as flecainide's proarrhythmic risk increases with electrolyte abnormalities 5
- Monitor ECG parameters closely: PR interval (watch for >0.3 seconds), QRS duration (caution if >0.18 seconds), and QTc interval 5, 6
- Ensure continuous cardiac monitoring in the immediate perioperative period, as flecainide can cause conduction abnormalities including sinus pause, AV block, and bradycardia 5
Contraindications and High-Risk Scenarios
Do not use flecainide perioperatively in patients with:
- Structural heart disease or coronary artery disease 7
- History of myocardial infarction 7
- Heart failure (NYHA class III-IV) or ejection fraction <30% 5
- Severe left ventricular hypertrophy 7
These patients should have flecainide discontinued well before elective surgery and alternative rhythm management strategies employed.
Specific Perioperative Considerations
For patients with pacemakers or ICDs:
- Verify pacing thresholds before surgery, as flecainide increases endocardial pacing thresholds 5
- Ensure backup pacing capability is available
- Recheck thresholds one week postoperatively 5
Plasma level monitoring is strongly recommended perioperatively, particularly in:
- Patients with renal impairment (flecainide has 12-27 hour half-life) 5
- Those on concurrent amiodarone (reduce flecainide dose by 50%) 5
- Patients with hepatic disease 5
- Target trough levels: 0.2-1.0 mcg/mL (levels >1.0 mcg/mL increase adverse cardiac events) 5
Postoperative Restart Protocol
Since flecainide should be continued, no restart protocol is needed. However, if it was held:
- Resume at the same dose once hemodynamically stable
- Verify normal electrolytes before restarting
- Obtain baseline ECG to assess conduction parameters
- Monitor for 24-48 hours after reinitiation given the drug's long half-life 5
Common Pitfalls to Avoid
- Do not confuse flecainide management with anticoagulation protocols—the extensive perioperative anticoagulation guidelines 1, 2 do not apply to antiarrhythmics
- Avoid rapid atrial flutter with 1:1 conduction—the most dangerous perioperative complication with flecainide 8. Consider adding AV nodal blocking agents (beta-blockers, calcium channel blockers) if atrial flutter develops
- Do not restart flecainide in the setting of new heart failure or significant conduction abnormalities that developed perioperatively 5
- Recognize that stress, pain, and sympathetic surge in the perioperative period may precipitate arrhythmias despite flecainide therapy 8
Bridging Strategies
No bridging is required or recommended for flecainide, as it is not an anticoagulant. The concept of "bridging" applies only to anticoagulation management 1, 2, not to antiarrhythmic therapy.
Electrolyte Targets
Maintain strict electrolyte control perioperatively:
- Potassium: >4.0 mEq/L (ideally 4.0-5.0 mEq/L)
- Magnesium: >2.0 mg/dL
- These targets minimize proarrhythmic risk with class IC agents 7